These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 9127173)
21. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy. Amedei A; Niccolai E; Prisco D Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688 [TBL] [Abstract][Full Text] [Related]
23. Emerging drugs in pancreatic cancer. Ducreux M; Boige V; Malka D Expert Opin Emerg Drugs; 2004 May; 9(1):73-89. PubMed ID: 15155137 [TBL] [Abstract][Full Text] [Related]
24. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer. Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605 [TBL] [Abstract][Full Text] [Related]
26. Trial of therapy with monoclonal antibody 17-1A in pancreatic carcinoma: preliminary results. Sindelar WF; Maher MM; Herlyn D; Sears HF; Steplewski Z; Koprowski H Hybridoma; 1986 Jul; 5 Suppl 1():S125-32. PubMed ID: 3744377 [TBL] [Abstract][Full Text] [Related]
27. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts. Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495 [TBL] [Abstract][Full Text] [Related]
28. Studies of pancreatic cancer utilizing monoclonal antibodies. Büchler M; Friess H; Malfertheiner P; Schultheiss KH; Muhrer KH; Kraemer HP; Beger HG Int J Pancreatol; 1990; 7(1-3):151-7. PubMed ID: 1964470 [TBL] [Abstract][Full Text] [Related]
29. Implications of current therapeutic approaches in colorectal cancer for other gastrointestinal malignancies. Lembersky BC Semin Oncol; 1991 Feb; 18(1 Suppl 1):39-46. PubMed ID: 1992529 [TBL] [Abstract][Full Text] [Related]
30. [Therapy of pancreatic carcinoma with the monoclonal antibody BW 494/32: first clinical results]. Friess H; Büchler M; Schulz G; Beger HG Immun Infekt; 1989 Feb; 17(1):24-6. PubMed ID: 2925220 [TBL] [Abstract][Full Text] [Related]
31. Monoclonal antibodies in the therapy of multiple sclerosis: an overview. Rommer PS; Stüve O; Goertsches R; Mix E; Zettl UK J Neurol; 2008 Dec; 255 Suppl 6():28-35. PubMed ID: 19300957 [TBL] [Abstract][Full Text] [Related]
32. The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review). Oei AL; Sweep FC; Thomas CM; Boerman OC; Massuger LF Int J Oncol; 2008 Jun; 32(6):1145-57. PubMed ID: 18497976 [TBL] [Abstract][Full Text] [Related]
33. Immunotherapy in pancreatic cancer - current status and future. Staib L; Link KH; Beger HG Langenbecks Arch Surg; 1999 Aug; 384(4):396-404. PubMed ID: 10473862 [TBL] [Abstract][Full Text] [Related]
34. Percolation and binding of MAB BW 494 to pancreatic carcinoma tissues during high dose immunotherapy and consequences for future therapy modalities. Bosslet K; Keweloh HC; Hermentin P; Muhrer KH; Sedlacek HH; Schulz G Behring Inst Mitt; 1990 Dec; (87):68-75. PubMed ID: 2096821 [TBL] [Abstract][Full Text] [Related]
35. Novel agents for the treatment of pancreatic cancer. Brennan GT; Relias V; Saif MW JOP; 2014 Mar; 15(2):110-3. PubMed ID: 24618430 [TBL] [Abstract][Full Text] [Related]
36. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. Gillen S; Schuster T; Meyer Zum Büschenfelde C; Friess H; Kleeff J PLoS Med; 2010 Apr; 7(4):e1000267. PubMed ID: 20422030 [TBL] [Abstract][Full Text] [Related]
37. Immunological approach in the diagnosis, therapy and prognosis of the exocrine pancreatic cancer. Bădulescu F; Bădulescu A; Rogoz S; Mustaţă R Roum Arch Microbiol Immunol; 2001; 60(1):5-16. PubMed ID: 11850897 [TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group. Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153 [TBL] [Abstract][Full Text] [Related]